UNSPSC 51401541: Sarmazenil

This classification denotes an anxiolytic with the molecular formula C15H14ClN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F84AE7X24P, chemically known as ethyl 7-chloro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo-(1,5-a)(1,4)benzodiazepine-3-carboxylate but generally known as sarmazenil, which bears US NIH Compound Identifier 71231. European Medicines Agency schedules Sarmazenil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10452MIG.

UNSPSC 51401541 Sarmazenil is a Commodity code, but the recent state and local opportunities tagged under it do not involve sarmazenil procurement directly. Instead, the code shows activity centered on naloxone, generic multi-source pharmaceuticals, and over-the-counter products purchased by state health agencies, county health departments, and cooperative purchasing alliances. State and local governments use this code to procure pharmaceutical products for community health initiatives, pharmacy benefit programs, and multistate distribution networks, with vendors required to meet FDA compliance, Good Manufacturing Practice certification, and Drug Supply Chain Security Act requirements. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent opportunities reflect activity in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023, and a fixed-fee contract structure with a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with responses due the same day. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026; evaluation weighting favors price competitiveness at 75 percent, with mandatory 3 percent administrative fees and performance penalties up to $1,500 per violation.